SCHEMBL6576391

SCHEMBL6576391

CC(=O)Nc1ccc(C(=O)CCl)cn1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.58
TP53 P04637 2/20 0.58
PTK2 Q05397 1/20 0.58
HIF1A Q16665 1/20 0.58
GRIN2B Q13224 1/20 0.50
CYP1A2 P05177 1/20 0.49
GAA P10253 1/20 0.49
HCAR3 P49019 5/20 0.47
RAB9A P51151 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.45
EPHX2 P34913 1/20 0.45
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923544 0.85 PTK2 (0.56) PTK2GRIN2BCYP1A2GAAHCAR3
SCHEMBL16463469 0.85 PTK2 (0.56) PTK2GRIN2BCYP1A2GAAHCAR3
SCHEMBL1203341 0.84 PTK2 (0.54) PTK2GRIN2BCYP1A2GAAHCAR3
SCHEMBL4896861 0.83 ALDH1A1 (0.51) ALDH1A1TP53HIF1AHCAR3RAB9A
SCHEMBL16463731 0.83 PTK2 (0.53) PTK2GRIN2BCYP1A2GAAHCAR3
SCHEMBL7093993 0.81 PTK2 (0.62) TP53PTK2CYP1A2GAAHCAR3
SCHEMBL6926972 0.80 ALDH1A1 (0.50) ALDH1A1TP53PTK2GRIN2BCYP1A2
SCHEMBL82675 0.80 HCAR3 (0.68) PTK2CYP1A2GAAHCAR3
SCHEMBL25190504 0.78 PTK2 (0.59) TP53PTK2CYP1A2GAAHCAR3
SCHEMBL10589075 0.78 ALDH1A1 (0.54) ALDH1A1TP53PTK2HIF1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040265991-A1 Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives KANEKA CORPORATION (JP) 2004-12-30 US disclosed
EP-1454899-A1 PROCESS FOR PREPARATION OF (S)-ALPHA-HALOME THYLPYRIDINE METHANOL DERIVATIVES KANEKA CORPORATION (JP) 2004-09-08 EP disclosed
US-6642387-B2 Dehalogenation esterification; efficient; no toxic materials KANEKA CORPORATION (JP) 2003-11-04 US disclosed
US-20030130521-A1 Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same KANEKA CORPORATION (JP) 2003-07-10 US disclosed
US-6515134-B1 A production method of an optically active hydroxyethyl pyridine derivative represented by the general formula which comprises using a microorganism-derived carbonyl reducing enzyme or a culture of a microorganism having an ability of KANEKA CORPORATION (JP) 2003-02-04 US disclosed
EP-1153919-A1 SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME KANEKA CORPORATION (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130521-A1 Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same ADRB3, ADRB2, ADRB1 ALDH1A1 184/4885TP53 4883/4885PTK2 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.